On October 6, 2023, the Board of Directors of LivaNova PLC appointed J. Christopher Barry to the Board and as a member of the Audit and Compliance Committee of the Board. Mr. Barry, 51, has over 20 years of experience in the medical technology industry. Mr. Barry served as Chief Executive Officer and Director of NuVasive Inc. (?NuVasive?), a medical devices company, from November 2018 until NuVasive?s merger with Globus Medical Inc. in September 2023.

Prior to joining NuVasive, Mr. Barry served as Senior Vice President and President of Surgical Innovations for Medtronic plc, a global medical technology company, from January 2015 to October 2018. Previously, Mr. Barry spent 15 years with Covidien plc in various sales and leadership roles, most recently as President, Advanced Surgical Technologies, from October 2013 to January 2015. Consistent with the Company?s other non-employee directors, Mr. Barry will be compensated in accordance with the Company?s Remuneration Policy (the ?Policy?).

In connection with this appointment and pursuant to the Policy, Mr. Barry will receive an annual board retainer fee of $110,000, an Audit and Compliance Committee annual member fee of $15,000 and an annual, service-based restricted stock award grant with a fair market value of $130,000, in each case prorated for his service with respect to fiscal 2023. On October 6, 2023, Andrea Saia notified the Company of her decision to retire from the Board, effective December 31, 2023. Ms. Saia informed the Company that her decision to retire was not the result of any disagreement with the Company on any matter relating to the Company?s operations, policies, or practices.